Flexbumin 200 g/ L Norge - norsk - Statens legemiddelverk

flexbumin 200 g/ l

baxalta innovations gmbh - albumin, humant - infusjonsvæske, oppløsning - 200 g/ l

Cancidas (previously Caspofungin MSD) Den europeiske union - norsk - EMA (European Medicines Agency)

cancidas (previously caspofungin msd)

merck sharp & dohme b.v. - caspofungin (as acetate) - candidiasis; aspergillosis - antimykotika for systemisk bruk - treatment of invasive candidiasis in adult or paediatric patients;treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin b, lipid formulations of amphotericin b and / or itraconazole. refractoriness is defined as progression of infection or failure to improve after a minimum of seven days of prior therapeutic doses of effective antifungal therapy;empirical therapy for presumed fungal infections (such as candida or aspergillus) in febrile, neutropaenic adult or paediatric patients.

Erivedge Den europeiske union - norsk - EMA (European Medicines Agency)

erivedge

roche registration gmbh - vismodegib - karsinom, basalcelle - antineoplastiske midler - erivedge er indisert for behandling av voksne pasienter med:- symptomatisk metastatisk basal cell carcinoma - lokalt avansert basal cell carcinoma uegnet for kirurgi eller strålebehandling.

Vanflyta Den europeiske union - norsk - EMA (European Medicines Agency)

vanflyta

daiichi sankyo europe gmbh - quizartinib dihydrochloride - leukemi, myeloid - antineoplastic agents, protein kinase inhibitors - vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (aml) that is flt3-itd positive.

Cymevene 500 mg Norge - norsk - Statens legemiddelverk

cymevene 500 mg

cheplapharm arzneimittel gmbh - ganciklovirnatrium - pulver til konsentrat til infusjonsvæske, oppløsning - 500 mg

Rinvoq Den europeiske union - norsk - EMA (European Medicines Agency)

rinvoq

abbvie deutschland gmbh & co. kg - upadacitinib - leddgikt, reumatoid - immunsuppressive - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Orfiril 300 mg Norge - norsk - Statens legemiddelverk

orfiril 300 mg

desitin arzneimittel gmbh - natriumvalproat - enterotablett - 300 mg

Orfiril long 500 mg Norge - norsk - Statens legemiddelverk

orfiril long 500 mg

desitin arzneimittel gmbh - natriumvalproat - depotgranulat - 500 mg

Orfiril long 1000 mg Norge - norsk - Statens legemiddelverk

orfiril long 1000 mg

desitin arzneimittel gmbh - natriumvalproat - depotgranulat - 1000 mg

Orfiril long 150 mg Norge - norsk - Statens legemiddelverk

orfiril long 150 mg

desitin arzneimittel gmbh - natriumvalproat - depotkapsel, hard - 150 mg